Check out which companies are making headlines before the bell:
Foot Locker – Barclays upgraded the apparel and footwear retailer to "overweight" from "equal weight," saying the stock's price represents an attractive entry point given long term growth prospects as well as the potential boost from the company's upcoming 2015 investor day.
Shake Shack – The restaurant chain's shares will begin trading today after its initial public offering priced at $21 per share, above the expected range of $17 to $19 per share.
Eli Lilly – The drugmaker beat estimates by two cents with adjusted quarterly profit of 75 cents per share, although revenue was slightly below estimates. Lilly gave an upbeat assessment of its long term prospects despite the current impact of patent expirations and having to cut its revenue estimate because of a stronger U.S. dollar.
Tyco – The fire protection and security company matched estimates with profit of 49 cents per share, but also said unfavorable foreign exchange rates will impact the company's bottom line in 2015 by 16 cents per share. It had previously forecast a seven cent impact.
Weyerhaeuser – The forest products company earned an adjusted 27 cents per share for its latest quarter, two cents short of estimates, with revenue essentially in line. The company did benefit from an improving housing market, but saw a drop in its timberlands business.
Xerox – Xerox earned 31 cents per share for its latest quarter, two cents above estimates, but revenue came in slightly below as printer sales fell. Xerox also raised its quarterly dividend to seven cents per share from 6.25 cents.
Tyson Foods – The beef and poultry producer earned an adjusted 77 cents per share, four cents above estimates, with revenue also beating consensus. Tyson also said its integration of Hillshire Brands is going well.
Newell Rubbermaid – The household products maker earned an adjusted 49 cents per share for its fourth quarter, one cent above estimates, with revenue also beating consensus. Its results were helped by higher prices, stronger volume, and acquisitions.
Dick's Sporting Goods – Dick's CEO Edward Stack is leaning towards keeping control of the company rather than a sale, according to a report in the New York Post.
Amazon.com – Amazon reported quarterly profit of 45 cents per share, well above estimates of 17 cents. The online retailer's revenue, however, was slightly below, as was its current quarter revenue guidance. However, much of that came from an unfavorable impact from foreign exchange rates.
Google - Google earned $6.88 per share for its latest quarter, missing estimates of $7.11. Revenue also came in below forecasts, with Google hurt by lower advertising prices as well as unfavorable foreign exchange rates.
Visa – Visa beat estimates by four cents with quarterly profit of $2.53 per share, and revenue was above forecasts as well. Visa also announced a four-for-one stock split.
Biogen Idec – Biogen earned an adjusted $4.09 per share for its latest quarter, beating estimates of $3.77. Revenue matched forecasts, and the biotech company's 2015 outlook is well above Street estimates. Biogen is being helped by strong sales of its Tecfidera treatment for multiple sclerosis.
Deckers – Deckers missed estimates by two cents with quarterly profit of $4.50 per share, with revenue also missing the mark. The maker of footwear and apparel also cut its full year outlook, on weaker sales for its UGG shoes.
Manitowoc – Manitowoc will split into two separate companies, spinning off its food-services business sometime in 2016. It will keep its construction equipment business. Separately, the company reported quarterly profit of 27 cents per share, missing estimates by five cents.
Broadcom - Broadcom came in three cents above estimates with adjusted quarterly profit of 90 cents per share, with revenue above estimates as well. The chipmaker increased sales of Wi-Fi and broadband-related chips, and is also being helped by soaring sales at Apple, a key Broadcom customer.
Align Technology - Align missed estimates by one cent with quarterly profit of 48 cents per share, thought revenue was above forecasts. The maker of the Invisalign orthodontic system also gave a current quarterly forecast that falls below Street estimates.
Valeant Pharmaceuticals – Valeant will buy the cancer vaccine Provenge from bankrupt drug maker Dendreon for $296 million.